Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107236 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction
A Phase 2 study of Healthy, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT01107236: Completed Phase 2 study of Healthy, sponsored by Ironwood Pharmaceuticals.
NCT01107236 is a Phase 2 study of Healthy that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 90 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01107236, a Phase 2 study of Healthy, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety of IW-6118 when administered as a single oral dose to patients undergoing third molar extraction. Efficacy will be assessed in an exploratory manner.
Conditions Studied
Interventions
- DRUG Matching Placebo
- DRUG IW-6118
- DRUG Naproxen Sodium
Study Locations (1)
Utah
- Ironwood Investigational Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01107236
The ClinicalTrials.gov registry entry for NCT01107236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (86% lower). The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Matching Placebo is the first listed.
NCT01107236 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT01107236 about?
NCT01107236 is a clinical study titled "Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction". The purpose of this study is to assess the safety of IW-6118 when administered as a single oral dose to patients undergoing third molar extraction. Efficacy will be assessed in an exploratory manner.
What is the current status of trial NCT01107236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2010-06. Estimated completion is 2010-08.
What conditions does trial NCT01107236 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01107236?
The interventions under investigation include: Matching Placebo (DRUG), IW-6118 (DRUG), Naproxen Sodium (DRUG).
Who is sponsoring clinical trial NCT01107236?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01107236 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Atenolol for the Prevention of Osteoporosis (APO)
ACTIVE NOT RECRUITING · Phase 2
-
Effectiveness of Aquamin® in Mitigating Halitosis
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.